Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Onbrez

- PMLiVE

Ruder Finn launches a social media meningitis campaign

The awareness campaign involves collaboration with three UK meningitis charities

Novartis’ COPD drug Seebri cleared in EU and Japan

Used with Breezhaler device in Europe and inhalation capsule in Japan

Novartis’ Peter Maag appointed president and CEO of XDx

Joins following launch of AlloMap test for transplant patients

- PMLiVE

VIDEO: Eisai manufacturing plans shows UK is recovering from ‘shock’ of Pfizer/AZ cutbacks

David Willetts says life sciences industry has future in UK at opening of Fycompa manufacturing site

Novartis drug effective in hard-to-treat psoriasis

Secukinumab to commence phase III trials

Novartis building

Novartis heart failure candidate clears phase III trial

Serelaxin proves effective in reducing all-cause mortality

Novartis building

CHMP backs trio of Novartis products

Including two diabetes drugs and one for non-cancerous kidney tumours

Novartis building

Novartis signs $665m option deal with Selexys

Would acquire biotech company and its sickle cell disease drug

Eisai launches epilepsy drug Fycompa in UK

CEO of Eisai EMEA Gary Hendler says UK “last free pricing market in Europe”

- PMLiVE

Roche loses Indian Tarceva patent battle with Cipla

As Novartis' Glivec patent law challenge begins again

FDA sued for approving high dose of Eisai’s Alzheimer’s drug Aricept

Consumer rights group Public Citizen claims the high-strength dose is unsafe

Novartis building

FDA panel backs Novartis’ updated cystic fibrosis drug

New version of inhaled tobramycin therapy is simpler to use

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links